Generated by AI
Summit Therapeutics Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing therapies for serious unmet medical needs. Summit Therapeutics Inc. centers its current portfolio on oncology, with ivonescimab as its lead investigational asset, a bispecific antibody designed to combine immune checkpoint blockade with anti-angiogenic activity. The company is advancing ivonescimab in multiple late-stage clinical programs for non-small cell lung cancer and colorectal cancer, often in combination with chemotherapy. Summit Therapeutics Inc. also maintains an anti-infectives program, including ridinilazole, an oral antibiotic candidate studied for Clostridioides difficile infection. Through these product and development efforts, Summit Therapeutics Inc. plays a role in precision medicine across cancer and infectious disease, with a focus on therapies intended to address difficult-to-treat conditions.
Website601 Brickell Key Drive
Miami, FL, 33131
United States
The latest articles about SMMT.
Summit Therapeutics (SMMT) stock slips as Bernstein downgrades the company to Underperform from Market Perform, citing concern over its R&D efforts. Read more here.
The U.S. regulator’s disclosure was more extensive than what the biotech company had announced Sunday.
Summit Therapeutics has seen its modeled fair value per share edge down from US$30.07 to US$29.41, which gives you an updated reference point for where some analysts see long term worth. This subtle shift lines up with recent research that weighs the US$2b AstraZeneca partnership and lung cancer program optimism against questions on valuation, trial outcomes, and competitive pressures. As you read on, you will see how these moving targets shape the evolving analyst story around Summit...
Summary of Nov 18's posts. Generated by AI.
Summary of Nov 17's posts. Generated by AI.
Summary of Sep 29's posts. Generated by AI.
Summary of Nov 18's posts. Generated by AI.
Investors talking about SMMT also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.